MOHNYSEHospital & Medical Service PlansFiscal year ends December 31
MOLINA HEALTHCARE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$210.20+2.84 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $10.78B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
13.1%+0.3 pts over 5 years
Operating margin
1.7%−3.8 pts over 5 years
Net margin
1.0%−2.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.7% | +12.4% | +18.5% | +12.3% | |
| Gross profit | -4.6% | +7.4% | +19.1% | +14.5% | |
| Operating income | -54.2% | -12.7% | -6.2% | +7.3% | |
| Net income | -60.0% | -15.8% | -6.8% | +12.7% | |
| EPS, diluted | -56.3% | -13.0% | -4.5% | +13.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 3.2% | 33.2% | 11.0% | |
| Return on assets | 0.7% | 8.2% | 3.0% | |
| Current ratio | 1.31 | 1.59 | 1.69 | |
| Debt to equity | 0.88 | 1.01 | 0.93 | |
| Net debt to EBITDA | -3.00× | -1.80× | -0.49× | |
| Interest coverage | 3.0× | 10.6× | 4.1× | |
| Capex to revenue | 1.0% | 0.4% | 0.2% | |
| Diluted shares | 56M | 60M | 53M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Molina Healthcare generated $5.73B from operations and spent $2.98B on capital expenditure, dividends and share buybacks. 15% of that went back into the business.
Generated
$5.73B
Used
$2.98B
Capital expenditure$453.00M15%Dividends$00%Share buybacks$2.53B85%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1.0%
×Asset turnover2.91×
×Equity multiplier3.64×
=Return on equity, FY202511.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 1.0% | 2.91× | 3.64× | 11.0% |
| FY2024 | 2.9% | 2.66× | 3.50× | 27.1% |
| FY2023 | 3.2% | 2.50× | 3.79× | 30.4% |
| FY2022 | 2.5% | 2.61× | 4.38× | 28.3% |
| FY2021 | 2.4% | 2.55× | 4.60× | 27.9% |
| FY2020 | 3.5% | 2.38× | 4.02× | 33.2% |
| FY2019 | 4.4% | 2.41× | 3.86× | 40.9% |
| FY2018 | 3.7% | 2.42× | 5.24× | 47.4% |
| FY2017 | -2.6% | 2.50× | 5.33× | -34.3% |
| FY2016 | 0.3% | 2.54× | 4.37× | 3.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$472.00M
- Cash generatingOperating cash flow above zero-$535.00M
- Return on assets improvedROA up on the prior year7.9% → 3.0%
- Earnings backed by cashOperating cash flow above net income-$535.00M vs $472.00M
- Less leverageLong-term debt to assets fell18.7% → 24.2%
- Better liquidityCurrent ratio rose1.62 → 1.69
- No dilutionShare count did not rise58M → 53M
- Gross margin improvedGross margin up on the prior year15.31% → 13.07%
- More efficientAsset turnover rose2.73 → 2.91